EUVIMEDEUVIMED entdecken
Open Access

Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes

William Wang, Nora D Volkow iD, Nathan A Berger iD, Pamela B Davis iD, David C Kaelber iD, Rong Xu iD

Annals of Internal Medicine · 2024

DOI: 10.7326/m23-2718 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von William Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio (W.W., N.A.B.). Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Tobacco Use Disorder. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIAAA NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Reports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest about its potential benefit for tobacco use disorders (TUDs). OBJECTIVE: To examine the association of semaglutide with TUD-related health care measures in patients with comorbid T2DM and TUD. DESIGN: Emulation target trial based on a nationwide population-based database of patient electronic health records. SETTING: United States, 1 December 2017 to 31 March 2023. PARTICIPANTS: Seven target trials were emulated among eligible patients with comorbid T2DM and TUD by comparing the new use of semaglutide versus 7 other antidiabetes medications (insulins, metformin, dipeptidyl-peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, thiazolidinediones, and other GLP-1RAs). MEASUREMENTS: The TUD-related health care measures (medical encounter for diagnosis of TUD, smoking cessation medication prescriptions, and smoking cessation counseling) that occurred within a 12-month follow-up were examined using Cox proportional hazards and Kaplan-Meier survival analyses. RESULTS: The study compared 222 942 new users of antidiabetes medications including 5967 of semaglutide. Semaglutide was associated with a significantly lower risk for medical encounters for TUD diagnosis compared with other antidiabetes medications, and was strongest compared with insulins (hazard ratio [HR], 0.68 [95% CI, 0.63 to 0.74]) and weakest but statistically significant compared with other GLP-1RAs (HR, 0.88 [CI, 0.81 to 0.96]). Semaglutide was associated with reduced smoking cessation medication prescriptions and counseling. Similar findings were observed in patients with and without a diagnosis of obesity. For most of the group comparisons, the differences occurred within 30 days of prescription initiation. LIMITATION: Documentation bias, residual confounding, missing data on current smoking behavior, body mass index, and medication adherence. CONCLUSION: Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid T2DM and TUD compared with other antidiabetes medications including other GLP-1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide's potential for TUD treatment. PRIMARY FUNDING SOURCE: National Institutes of Health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsTobacco Use DisorderHumansFemaleMaleMiddle AgedAgedUnited StatesSmoking CessationObesitySemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio (W.W., N.A.B.).
  • National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland (N.D.V.).
  • Center for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, Ohio (P.B.D.).
  • Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio (D.C.K.).
  • Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio (R.X.).

ORCID-Profile: Nora D Volkow, Nathan A Berger, Pamela B Davis, David C Kaelber, Rong Xu

Förderung

  • NIA NIH HHS
  • NIAAA NIH HHS
  • NCATS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024). Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes. Annals of Internal Medicine. https://doi.org/10.7326/m23-2718

Vancouver

Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes. Annals of Internal Medicine. 2024. doi:10.7326/m23-2718

BibTeX
@article{Wang2024,
  author = {Wang, William and Volkow, Nora D and Berger, Nathan A and Davis, Pamela B and Kaelber, David C and Xu, Rong},
  title = {Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes},
  journal = {Annals of Internal Medicine},
  year = {2024},
  doi = {10.7326/m23-2718}
}
Kostenlos starten →